Core Viewpoint - Allergy Therapeutics is evaluating the possibility of a dual primary listing on the Hong Kong Stock Exchange while retaining its listing on the AIM market, aiming to complete the listing by the first half of 2026 [1] Group 1: Company Strategy - The company aims to expand its business footprint in Asia and become a leader in the global allergy treatment sector [1] - A listing on the Hong Kong Stock Exchange is expected to broaden the investor base by including investors from Hong Kong and mainland China, aligning with the company's growth objectives in the region [1] - The dual listing is anticipated to enhance the liquidity of its ordinary shares [1] Group 2: Company Background - Allergy Therapeutics is a UK-based biotechnology company focused on allergy immunotherapy [1]
英国生物医药公司Allergy Therapeutics考虑赴港上市
Zhi Tong Cai Jing·2025-11-07 12:37